Source 1primary paper2026MED
Toolkit/Adeno-associated virus (AAV) gene therapy
Adeno-associated virus (AAV) gene therapy
Also known as: AAV gene therapy
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Adeno-associated virus (AAV) gene therapy is a promising approach for hemophilia, offering the potential for sustained therapeutic expression of coagulation factors.
Usefulness & Problems
Why this is useful
AAV gene therapy is presented as a liver-directed approach for hemophilia that can provide sustained expression of coagulation factors. The review focuses on why expression varies and declines over time despite vector persistence.; liver-directed gene delivery for hemophilia; sustained therapeutic expression of coagulation factors
Source:
AAV gene therapy is presented as a liver-directed approach for hemophilia that can provide sustained expression of coagulation factors. The review focuses on why expression varies and declines over time despite vector persistence.
Source:
liver-directed gene delivery for hemophilia
Source:
sustained therapeutic expression of coagulation factors
Problem solved
It aims to reduce hemophilia burden by enabling long-term therapeutic coagulation factor expression after gene transfer.; enables therapeutic coagulation factor expression for hemophilia
Source:
It aims to reduce hemophilia burden by enabling long-term therapeutic coagulation factor expression after gene transfer.
Source:
enables therapeutic coagulation factor expression for hemophilia
Problem links
enables therapeutic coagulation factor expression for hemophilia
LiteratureIt aims to reduce hemophilia burden by enabling long-term therapeutic coagulation factor expression after gene transfer.
Source:
It aims to reduce hemophilia burden by enabling long-term therapeutic coagulation factor expression after gene transfer.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
epigenetic modulation of transgene expressionimmune-mediated effects on transgene durabilitytranscriptional regulation of transgene expressiontranslation controlTranslation Controlviral gene delivery to hepatocytesTechniques
No technique tags yet.
Target processes
transcriptiontranslationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: delivery
The abstract implies delivery of an AAV vector carrying a coagulation factor transgene into hepatocytes. Durable benefit also depends on favorable transcriptional efficiency and limited cellular stress or immune-mediated loss.; therapeutic efficacy is not predicted by vector genome copy number alone; expression depends on transcriptional efficiency and host-cell factors
It does not by itself guarantee predictable or durable expression, because variability persists across species and individuals and can be affected by genome loss, immune responses, and cellular stress.; variability of transgene expression limits treatment predictability; durability of transgene expression remains a challenge
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Vector genome retention is relatively comparable across species, but transcriptional efficiency declines in higher species including non-human primates, dogs, and humans.
While vector genome retention is relatively comparable across species, transcriptional efficiency declines in higher species, particularly in NHPs, dogs, and humans.
Vector genome loss, hepatocyte turnover, immune responses, cellular stress, epigenetic modifications, vector integration patterns, and translational shutdown linked to protein-folding stress may contribute to declining transgene expression durability.
Beyond transcription, vector genome loss, hepatocyte turnover, immune responses, and cellular stress (e.g., endoplasmic reticulum (ER) stress) may contribute to intraindividual declines in transgene expression over time. Recent findings also highlight the role of epigenetic modifications, vector integration patterns, and translational shutdown linked to protein-folding stress in influencing durability.
Transcriptional efficiency rather than vector genome copy number is a primary determinant of variability and durability in AAV hemophilia gene therapy response.
Comparative preclinical and human liver biopsy studies suggest that transcriptional efficiency, rather than vector genome copy number (VCN), is a primary determinant of variability and durability in treatment response.
Vector genome copy number alone is insufficient to predict therapeutic efficacy because transcriptional output varies across species and individuals despite vector genome presence in hepatocytes.
Despite the presence of vector genomes in hepatocytes, transcriptional output varies significantly across species and individuals, indicating that VCN alone is insufficient to predict therapeutic efficacy.
Approval Evidence
1 source4 linked approval claimsfirst-pass slug adeno-associated-virus-aav-gene-therapy
Adeno-associated virus (AAV) gene therapy is a promising approach for hemophilia, offering the potential for sustained therapeutic expression of coagulation factors.
Source:
cross species comparisonsupports
Vector genome retention is relatively comparable across species, but transcriptional efficiency declines in higher species including non-human primates, dogs, and humans.
While vector genome retention is relatively comparable across species, transcriptional efficiency declines in higher species, particularly in NHPs, dogs, and humans.
Source:
mechanistic contributorssupports
Vector genome loss, hepatocyte turnover, immune responses, cellular stress, epigenetic modifications, vector integration patterns, and translational shutdown linked to protein-folding stress may contribute to declining transgene expression durability.
Beyond transcription, vector genome loss, hepatocyte turnover, immune responses, and cellular stress (e.g., endoplasmic reticulum (ER) stress) may contribute to intraindividual declines in transgene expression over time. Recent findings also highlight the role of epigenetic modifications, vector integration patterns, and translational shutdown linked to protein-folding stress in influencing durability.
Source:
mechanistic determinantsupports
Transcriptional efficiency rather than vector genome copy number is a primary determinant of variability and durability in AAV hemophilia gene therapy response.
Comparative preclinical and human liver biopsy studies suggest that transcriptional efficiency, rather than vector genome copy number (VCN), is a primary determinant of variability and durability in treatment response.
Source:
predictive limitationsupports
Vector genome copy number alone is insufficient to predict therapeutic efficacy because transcriptional output varies across species and individuals despite vector genome presence in hepatocytes.
Despite the presence of vector genomes in hepatocytes, transcriptional output varies significantly across species and individuals, indicating that VCN alone is insufficient to predict therapeutic efficacy.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts different AAV hemophilia gene therapy contexts, especially FIX versus FVIII programs, rather than non-AAV alternatives.
Source:
The abstract contrasts different AAV hemophilia gene therapy contexts, especially FIX versus FVIII programs, rather than non-AAV alternatives.
Source-backed strengths
offers potential for sustained transgene expression
Source:
offers potential for sustained transgene expression
Compared with gene therapy
The abstract contrasts different AAV hemophilia gene therapy contexts, especially FIX versus FVIII programs, rather than non-AAV alternatives.
Shared frame: source-stated alternative in extracted literature
Strengths here: offers potential for sustained transgene expression.
Relative tradeoffs: variability of transgene expression limits treatment predictability; durability of transgene expression remains a challenge.
Source:
The abstract contrasts different AAV hemophilia gene therapy contexts, especially FIX versus FVIII programs, rather than non-AAV alternatives.
Ranked Citations
- 1.